Deprescribing: Fashion Accessory or Fig Leaf?

por Zermansky, Arnold G.
Publicado 2019

Biologicals and Biosimilars in Hematology: The Case of Rituximab

por Vulto, Arnold G.
Publicado 2019

Interchangeability of Biosimilars: Overcoming the Final Hurdles

por Barbier, Liese, Vulto, Arnold G.
Publicado 2021

2nd International Conference on Radiation Effects in Insulators

por Arnold, G W, Borders, J A
Publicado 1984

Risk management of biosimilars in oncology: each medicine is a work in progress

por Vulto, Arnold G., Crow, Stacy A.
Publicado 2012

The process defines the product: what really matters in biosimilar design and production?

por Vulto, Arnold G., Jaquez, Orlando A.
Publicado 2017

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?

por Moorkens, Evelien, Vulto, Arnold G., Huys, Isabelle
Publicado 2020

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

por Simoens, Steven, Vulto, Arnold G., Dylst, Pieter
Publicado 2021

The scale of repeat prescribing – time for an update

por Petty, Duncan R, Zermansky, Arnold G, Alldred, David P
Publicado 2014

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

por Dutta, Binita, Huys, Isabelle, Vulto, Arnold G., Simoens, Steven
Publicado 2019

Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure

por Cornes, Paul, Gascon, Pere, Vulto, Arnold G., Aapro, Matti
Publicado 2020

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice

por Barbier, Liese, Simoens, Steven, Vulto, Arnold G., Huys, Isabelle
Publicado 2020

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption

por Barbier, Liese, Simoens, Steven, Vulto, Arnold G., Huys, Isabelle
Publicado 2020

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis

por Barcina Lacosta, Teresa, Vulto, Arnold G., Huys, Isabelle, Simoens, Steven
Publicado 2022

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain

por Barcina Lacosta, Teresa, Vulto, Arnold G., Huys, Isabelle, Simoens, Steven
Publicado 2023

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?

por Moorkens, Evelien, Broux, Hannah, Huys, Isabelle, Vulto, Arnold G., Simoens, Steven
Publicado 2020

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking

por Barbier, Liese, Simoens, Steven, Declerck, Paul, Vulto, Arnold G., Huys, Isabelle
Publicado 2022

Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines

por Vandenplas, Yannick, Simoens, Steven, Turk, Florian, Vulto, Arnold G., Huys, Isabelle
Publicado 2022

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends

por Car, Elif, Vulto, Arnold G., Houdenhoven, Mark Van, Huys, Isabelle, Simoens, Steven
Publicado 2023